Copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Aug 14, 2020; 26(30): 4378-4393
Published online Aug 14, 2020. doi: 10.3748/wjg.v26.i30.4378
Published online Aug 14, 2020. doi: 10.3748/wjg.v26.i30.4378
Regulation of the intestinal microbiota: An emerging therapeutic strategy for inflammatory bowel disease
Bei Yue, Zhi-Lun Yu, Cheng Lv, Xiao-Long Geng, Zheng-Tao Wang, Wei Dou, The MOE key Laboratory of Standardization of Chinese Medicines, Shanghai Key Laboratory of Compound Chinese Medicines, and the SATCM key Laboratory of New Resources and Quality Evaluation of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
Author contributions: Yue B wrote the manuscript; Yu ZL, Lv C, Geng XL, Wang ZT and Dou W revised the manuscript and provided critical input.
Supported by National Natural Science Foundation of China , No. 81273572 and No. 81530096 ; and the Natural Science Foundation of Shanghai , No. 17ZR1427800 .
Conflict-of-interest statement: Authors declare no conflict of interests for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Wei Dou, PhD, Professor, Shanghai Key Laboratory of Compound Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, No. 1200 Cailun Road, Pudong New Area, Shanghai 201203, China. douwei123456@126.com
Received: March 13, 2020
Peer-review started: March 13, 2020
First decision: April 25, 2020
Revised: July 2, 2020
Accepted: July 4, 2020
Article in press: July 4, 2020
Published online: August 14, 2020
Peer-review started: March 13, 2020
First decision: April 25, 2020
Revised: July 2, 2020
Accepted: July 4, 2020
Article in press: July 4, 2020
Published online: August 14, 2020
Core Tip
Core tip: In this review, we explore therapies targeting intestinal microbiota, such as fecal bacteria transplantation, pro/prebiotics, and herbal medicinal products, that represent effective therapeutic options to control and slow the progression of inflammatory bowel disease (IBD). We also discuss some challenges and controversies in relation to these emerging therapeutic strategies. This has direct inspiration for researchers to overcome the current limitations of IBD therapies and shed light on personalized treatment options.